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Influenza-associated pulmonary aspergillosis (IAPA) has been reported increasingly since the advent of use
of neuraminidase (NA) inhibitors following the 2009 influenza pandemic. We hypothesize that blocking host
NA modulates the immune response against Aspergillus fumigatus. We demonstrate that NA influences the
host response against A. fumigatus in vitro and that oseltamivir increases the susceptibility of mice to pulmo-
nary aspergillosis. Oseltamivir impairs the mouse splenocyte and human peripheral blood mononuclear cell
(PBMC) killing capacity ofA. fumigatus, and adding NA restores this defect in PBMCs. Furthermore, the sialic
acid-binding receptor SIGLEC15 is upregulated in PBMCs stimulated with A. fumigatus. Silencing of
SIGLEC15 decrease PBMC killing of A. fumigatus. We provide evidence that host NA activity and sialic
acid recognition are important for anti-Aspergillus defense. NA inhibitors might predispose individuals
with severe influenza to invasive aspergillosis. These data shed light on the pathogenesis of invasive fungal
infections and may identify potential therapeutic targets.
INTRODUCTION
Influenza-associated pulmonary aspergillosis (IAPA) is an
emerging disease caused primarily by the ubiquitous fungus
Aspergillus fumigatus. Two recent studies show that the incidence
of IAPAamong individualswithsevere influenza isaround20%and
that themortality rate ismore than50%,whereas thenormal back-
ground incidence of invasive aspergillosis in the intensive care unit
(ICU) is 5%, and themortality of influenza is around 20%.1,2 A strik-
ing feature of IAPA is that the infection occurs in individualswithout
classic risk factors for invasive aspergillosis, and up to 30% of
cases occur in previously healthy individuals.1 The pathogenesis
of IAPA is not understood, which limits the clinical possibilities of
adequatediagnosis, treatment, and risk stratification.Understand-
ing the underlying mechanisms and interactions between the im-
mune system, the virus, and Aspergillus is essential.
Oseltamivir is a neuraminidase (NA) inhibitor that is adminis-
tered in virtually all individuals with severe influenza since the
H1N1 pandemic in 2009. Oseltamivir inhibits the NA activity of
the virus,3 which is needed for successful virus replication. The
virus cleaves sialic acid residues on the host cell surface that
subsequently allow the mature virion to be released. However,
humans and mice also express NAs, NEU1–NEU4, that mediate
diverse functions in host immune responses.4–7Mammalian cells
are covered in dense sialic acid sugars.8 Sialic acid-binding
immunoglobulin-like lectin (SIGLEC) receptors are expressed
on the surface of immune cells, and these receptors are usually
bound and, thus, masked by ‘‘self’’ sialic acids.9 In the presence
of NA, the receptors become unmasked, allowing them to bind
non-self sialylated ligands. A. fumigatus contains sialic acid
sugars on its cell walls that modulate immune responses.10 Inter-
estingly, treatment with oseltamivir has been associated with
increased platelet numbers in individuals with idiopathic throm-
bocytopenic purpura (ITP), supporting the concept that oselta-
mivir can also block human NA activity.11–13 Currently, two clin-
ical trials with oseltamivir in individuals with ITP are ongoing
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(NCT03520049 and NCT01965626), based on the fact that osel-
tamivir can block human NA activity and, in this way, alter sialic
acids on the surface of platelets.
Based on these data, we hypothesized that inhibition of NA for
treatment of influenza might predispose individuals to IAPA via
the effects of the NA inhibitor on host NA activity. Alteration of
host NA activity could potentially affect the host-Aspergillus
interaction, leading to increased susceptibility to invasive asper-
gillosis. The results of this study are important to unravel the un-
derlying mechanisms and pathogenesis of invasive pulmonary
aspergillosis following severe influenza, particularly in the setting
of clinical use of NA inhibitors.
RESULTS
NA activity modulates the host response to A. fumigatus
Previous literature has highlighted the role of human NA in medi-
ating the host immune response.14,15 However, the role of these
enzymes in modulating the host responses against A. fumigatus
has not been described. The cell wall of A. fumigatus contains
sialic acid residues that facilitate binding to epithelial cells in
the airway.10 To determine the role of NA in mediating host im-
mune responses against A. fumigatus, we first investigated
the effect of NA on the capacity of conidia to induce cytokine
responses. Peripheral blood mononuclear cells (PBMCs)
were stimulated with A. fumigatus conidia pretreated with
C. perfringensNA or mock treated. Production of tumor necrosis
factor alpha (TNF-a) and interleukin-1b (IL-1b) was increased
significantly in cells stimulatedwith NA-treated conidia, suggest-
ing that alteration of sialic acids on the surface of A. fumigatus
conidia influences the host response (Figure 1A). To confirm
that NA cleaved conidial glycans, A. fumigatus conidia were
incubated with Maackia amurensis lectin (MAL) II, Sambucus
nigra agglutinin (SNA), or peanut agglutinin (PNA) labeled with
a secondary fluorophore and analyzed by flowcytometry. We
observed that NA treatment of conidia reduces the amount of
(a2,3)-linked and (a2,6)-linked sialic acids (Figure S1).
Next we determined the effect of NA on host immune cells in
response to A. fumigatus conidia. PBMCs and neutrophils
were stimulated with A. fumigatus conidia in the presence or
absence of NA, and the production of cytokines was measured
from 24-h-stimulated culture supernatants. In the presence of
NA, PBMCs produced more TNF-a and IL-1b upon stimulation
with conidia (Figure 1B). Similarly, IL-8 production against
A. fumigatus was increased in neutrophils that were treated
with NA (Figure 1C). To confirm that the effect of NA was specific
to host immune cells, we also pre-treated cells with NA prior to
stimulation with A. fumigatus conidia. Similar to what we
observed, exposure of cells to exogenous NA enhanced cyto-
kine production in response to the fungus (Figure S2). To exclude
the possibility that the increased cytokine release was due to
lipopolysaccharide (LPS) contamination in the enzyme prepara-
tion, experiments were repeated in the presence of polymyxin B.
Addition of polymyxin B produced similar results: NA-treated
cells produced higher cytokine concentrations (Figure S2). We
further investigate whether A. fumigatus induces expression of
NEU genes in PBMCs. Indeed, NEU1, NEU3, and NEU4 expres-
sion was upregulated significantly in PBMCs after 4- and 24-h
stimulation with conidia (Figure 1D). These data suggest that
NA can modulate host immune responses against A. fumigatus
at the level of the pathogen and host immune cells.
NA inhibition increases susceptibility ofmice to invasive
aspergillosis
Because NA activity can modulate the host response against
A. fumigatus, we investigated whether blocking endogenous
NA with oseltamivir would affect cytokine responses against
A. fumigatus.Our resultsdemonstrate thatoseltamivir carboxylate
did not affect production of TNF-a and IL-1b by PBMCs (Fig-
ureS3). Therefore,weevaluated theeffect ofNA inhibitionbyosel-
tamivir in vivo and determined whether it would influence the sus-
ceptibility of mice to invasive pulmonary aspergillosis.
Immunocompetent C57BL/6 mice were treated with oseltamivir
twice daily for 5 consecutive days. On day 3 of treatment, mice
were infected intranasally with A. fumigatus (Figure 2A). On days
1 and 3 after infection, we measured the concentrations of cyto-
kines and fungal burden in lung homogenates. We observed that
mice treated with oseltamivir had a significantly higher fungal
burden in the lungs compared with PBS-treated controls at both
time points, suggesting that the fungus was not being cleared
effectively from the lungs (Figure 2B). Infected immunocompetent
mice treated with oseltamivir produced significantly higher TNF-a
and IL-10 comparedwith controlmiceonday 1after infection (Fig-
ure 2C), but there were no significant differences in IL-1b and IL-6
concentrations. On day 3 after infection, we did not observe any
differences between mice treated with oseltamivir and controls
in cytokine production except for IL-10. Determination of the total
number of immunecells present in the lungs by flowcytometry did
not show a significant difference in the total number ofmonocytes
and neutrophils in the lungs betweenoseltamivir-treated and con-
trol mice infected with A. fumigatus (Figure 2D). Histology of the
lung tissueshowed that, onday 1, therewere less inflammatory in-
filtrates in mice exposed to oseltamivir compared with controls,
whereas no differences were observed in the lungs on day 3 be-
tween the two groups (Figure 2E). Thus, despite normal cell
recruitment and intact cytokine responses, the mice showed a
higher fungal burden in the presence of NA inhibition.
Because invasive pulmonary aspergillosis usually occurs in the
setting of an underlying immunosuppressive condition, and in influ-
enza especially in the presence of corticosteroid use, we further
determined the effect of blocking NA in vivo in corticosteroid
(CS)-treated C57BL/6J mice. Immunosuppressed mice treated
with oseltamivir had significant lower survival compared with con-
trols (Figure 3A). Furthermore, the fungal burden in lung homoge-
nates of these mice was significantly higher than in control mice
(Figure 3B). We further determined whether oseltamivir could
affect the host response against A. fumigatus in the setting of
chemotherapy-induced immunosuppression. BALB/c mice were
immunosuppressedby intraperitonealadministrationofcyclophos-
phamide. Oseltamivir was given twice daily for 5 days, and
A. fumigatus was given intranasally on the third day of treatment.
Strikingly, we observed no significant differences in survival and
lung fungal burden in oseltamivir-treatedmice comparedwith con-
trols (Figures3Cand3D). Additionally, bioluminescent signals of re-
gions of interest covering the lungs ofA. fumigatus aswell as lesion
developmentwerenotdifferentbetweenthe twogroups (FigureS4).




Because we did not see an effect of oseltamivir on recruitment or
cytokine responses, and the effects on survival and fungal burden
were lost in the setting of depleted monocytes and neutrophils,
we hypothesized that the effect of blocking neuraminidase in vivo
on the host response against A. fumigatus might be mediated by
altered function of monocytes or neutrophils or both.
Blocking NA impairs fungal killing inmurine splenocytes
and human PBMCs
To further investigate whether NA inhibition modulates the anti-
fungal host defense of myeloid cells, we recovered splenocytes
from immunocompetent mice treated with oseltamivir or PBS




Figure 1. NA modulates the host response of PBMCs against A. fumigatus
(A) TNF-a and IL-1b concentrations in culture supernatants of PBMCs (n = 12) stimulated with 1 3 107/mL of mock- or NA-treated A. fumigatus conidia.
(B and C) PBMCs or neutrophils (n = 12) were stimulated with A. fumigatus conidia in the presence or absence of NA, and concentrations of TNF-a, IL-1b, or IL-8
were measured from 24-h-cultured supernatants.
(D) Gene expression profiling of the NEU genes in PBMCs (n = 8) that were stimulated with heat-killed A. fumigatus conidia for 4 and 24 h.16
Data are presented as mean ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05.




Figure 2. Oseltamivir affects the susceptibility of immunocompetent mice to A. fumigatus infection
(A) Immunocompetent C57BL/6J mice were treated with PBS (n = 20) or oseltamivir (10 mg/kg) (n = 20) twice daily for 5 consecutive days. On day 3 of treatment,
mice were infected intranasally with A. fumigatus or remained uninfected (naive). All mice were sacrificed on days 1 and 3 after infection.
(B) Fungal burden in lung homogenates on days 1 and 3 after infection (log10).
(legend continued on next page)




of these cells to kill A. fumigatus conidia was evaluated ex vivo.
We observed that splenocytes from oseltamivir-treated mice
had a marked decrease in the capacity to kill conidia compared
with splenocytes from untreated mice (Figure 4A). Strikingly,
similar findings were observed in murine splenocytes of mice
treated with oseltamivir but not infected with A. fumigatus. To
validate these findings in the human setting, we analyzed the
killing capacity of PBMCs and neutrophils against A. fumigatus
in the presence or absence of oseltamivir carboxylate, the active
metabolite of oseltamivir. Our data show that the capacity to kill
A. fumigatus was decreased in oseltamivir-treated compared
with untreated PBMCs (Figure 4B), but killing was unaffected in
neutrophils (Figure 4C). NA inhibition did not decrease reactive
oxygen species (ROS) production in vivo or in vitro and was
even associated with increased ROS production in vitro in neu-
trophils (Figures 4D–4G).
The role of SIGLEC15 in the host immune defense
against A. fumigatus
Our data suggest that the fungal capacity of mononuclear cells is
altered by NA inhibition. Therefore, we performed killing assays
in PBMCs in the presence or absence of NA to determine
whether the effect of NA activity acts directly on these cells. In
line with these observations, addition of NA enhanced the killing
capacity of PBMCs against A. fumigatus (Figure 5A) but did not
affect neutrophil killing function (Figure 5B). SIGLECs are a family
of receptors that regulate different immune functions,17 and
these receptors are densely covered sialic acids from other re-
ceptors on the same cell surface. In the presence of NA, SIGLEC
receptors become unmasked and can bind other sialylated li-
gands with higher sialic acid density. To investigate whether
A. fumigatus induces expression of SIGLEC genes in PBMCs,
we examined RNA sequencing (RNA-seq) from an existing data-
set.16 We identified one SIGLEC receptor that was upregulated
significantly after exposure toAspergillus,SIGLEC15 (Figure 5C).
Expression ofSIGLEC15was upregulated after 4- and 24-h stim-
ulation with conidia, although, after correction for multiple
testing, only 24-h expression remained significant. We further
investigated the interaction of this particular receptor with
A. fumigatus using flow cytometry. Following incubation of con-
idia with recombinant SIGLEC15 (recSIGLEC15), we observed
an increased fluorescent signal under recSIGLEC15-treated
conditions, providing evidence that recSIGLEC15 binds to
A. fumigatus (Figure 5D). To further explore the involvement of
SIGLEC15 in A. fumigatus killing, SIGLEC15 expression was
silenced in PBMCs. Cells treated with SIGLEC15-targeting small
interfering RNA (siRNA) exhibited decreased fungicidal activity
compared with control siRNA-treated cells (Figure 5E). We also
noted that silencing of SIGLEC15 reduced the expression of
IL10 and TGFB, both which are known as downstream effectors
of the receptor.18 However, we did not observe significant differ-
ences in TNF-a production induced by A. fumigatus as well as
zymosan-induced ROS in SIGLEC15-silenced cells and controls
(Figure S5). The cell wall of Aspergillus spp. conidia contains
sialic acid residues.10 Because the SIGLEC15 receptor can
bind to sialic acids, we explored whether removal of sialic acids
from A. fumigatuswould affect killing in the presence or absence
of SIGLEC15. Stimulation of SIGLEC15-silenced cells with NA-
treated conidia did not affect the killing capacity of these cells
compared with mock-treated conidia (Figure 5F). This suggests
that SIGLEC15-mediated killing requires the presence of sialic
acids on the surface of A. fumigatus conidia. To further deter-
mine the role of SIGLEC15 in the host defense against
A. fumigatus, we evaluated cytokine production from PBMCs
of individuals harboring a polymorphism in SIGLEC15
(rs2919643). In response to A. fumigatus conidia, individuals
carrying the disease-associated C allele had significantly lower
IL-1b and interferon g (IFN-g) concentration, whereas other cyto-
kines were unaffected (Figure 5G). Our results indicate that SI-
GLEC15 might be important in anti-Aspergillus host defense
and further strengthens the theory of a role of NA activity and
sialic acid recognition in the host immune response against
A. fumigatus.
DISCUSSION
IAPA has been reported increasingly since the 2009 flu
pandemic, and the pathogenesis of this disease is complex
and not well understood. Because sialic acid residues and re-
ceptors recognizing sialic acids play a key role in immunity,8,9,17
we hypothesized that the NA inhibitors that are used to treat
influenza might impair the host defense against Aspergillus and
therefore play a role in the increased susceptibility of individuals
with influenza to invasive aspergillosis. We demonstrate that NA
influences the host response toA. fumigatus, and inhibition of NA
in vivo increased the susceptibility of mice to invasive aspergil-
losis. We observed that NA activity is important for optimal
Aspergillus killing capacity of mononuclear cells in mice and hu-
man cells. We further demonstrate that SIGLEC15, a receptor on
myeloid cells that recognize sialic acids, plays a role in killing of
A. fumigatus. Thus, we provide evidence that NA activity and
SIGLEC15 play a role in anti-Aspergillus host defense, opening
a field in the pathogenesis of invasive fungal infection that is
unexplored.
Our in vitro data suggest that sialic acid recognition and NA ac-
tivity are vital for host-Aspergillus interaction. Enzymatic removal
of sialic acids on fungal and/or host cells modulates host re-
sponses against conidia, and this effect was not due to endo-
toxin-induced effects in the setting of the experiments with the
exogenous enzyme. We also demonstrate that A. fumigatus con-
idia contain (a2,3)-linked and (a2,6)-linked sialic acid residues.
This is relevant with regard to previous studies reporting that
the cell walls of A. fumigatus conidia contain negatively charged
sugars10,19 that are necessary for fungal adhesion to laminin
(C) Production of TNF-a, IL-1b, IL-6, and IL-10 was measured from lung homogenates of uninfected (striped bars) or infected (empty bars) mice that were treated
with oseltamivir (red bars) or remained untreated (black bars).
(D) The total number of immune cells in lung homogenates from infected or uninfected mice treated with oseltamivir or controls.
(E) Representative histology of the lung tissue sections of the mice on day 1 and day 3 after infection, stained with H&E.
Data are presented as mean ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05.




and fibronectin in respiratory epithelial tissues.10,20 Sialic acid res-
idues are also present abundantly on the cell surface of human
cells, where they mediate various functions in infection and
inflammation.21 Sialic acids comprise an important part of adhe-
sion molecules, which mediate leukocyte migration and adhe-
sion.8 The presence of NA activity, which can cleave off these
sialic acids, is thus likely to play a role in modulating host-path-
ogen interactions. A study by Amith et al.5 shows that binding of
pathogen-associated molecular patterns (PAMPs) to Toll-like re-
ceptor 2 (TLR2), TLR3, and TLR4 was able to induce NA activity
via Neu-1 expression in bone marrow-derived macrophages.
Neu-1 is important for TLR4 activation because it removes
a-2,3-sialyl residues linked to b-galactosidases on the surface
of TLR4. Removal of these sialic acid residues leads to receptor
TLR4 dimerization and nuclear factor kB (NF-kB) signaling.6,22
Neutrophils also express NAs that can desialylate several glyco-
proteins on the cell surface and facilitate binding to other cells.23
NAs present in T-lymphocytes have been shown to remove sialic
acids fromspecific glycoconjugates on the cell surface, leading to
enhanced IFN-g production.7,24 A. fumigatus also produces siali-
dase (KDNase), which specifically cleaves the sialic acid sub-
strate 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN),
and had lower activity in cleaving Neu5Ac from glycan struc-
tures25. Although the fungal sialidase gene could be induced by
the presence of serum, it is questionable whether KDNase would
affect host glycans because of its substrate specificity and limited
abundance in lower vertebrates and bacteria.26,27 Our data add
another layer of evidence showing that NA activity can modulate
host-pathogen interactions via mononuclear cells.
These observations become especially important in the
setting of IAPA. We have seen an increase in invasive aspergil-
losis in the ICU in individuals with influenza since the pandemic
in 2009.1,2,28,29 To date, studies show an incidence of around
20% of IAPA in the ICU,1 with many individuals not having the
Figure 3. The effect of oseltamivir on immu-
nocompromised mice
(A and B) Corticosteroid-treated C57BL/6J mice
were treated with PBS or oseltamivir (10 mg/kg)
twice daily for 5 days and infected with
A. fumigatus (1 3 107) via the intranasal route.
(A) Kaplan-Meier survival plot of mice infected with
A. fumigatus. Results were derived from three in-
dependent experiments (total n = 24 mice per
group).
(B) Fungal burden in lung homogenates of mice on
day 2 after infection. ***p < 0.001.
(C and D) BALB/c mice were treated with oselta-
mivir (10 mg/kg, n = 10) or PBS (n = 10) twice per
day for 5 days and infected intranasally with
A. fumigatus. Immunosuppression was induced
by intraperitoneal administration of cyclophos-
phamide (150 mg/kg). Shown are Kaplan-Meier
survival plot (C) from mice after 3 days of infection
and fungal burden (D) measured from lung ho-
mogenates.
classic risk factors for IA and even being
healthy before admission to the ICU.
Virtually all individuals with severe influ-
enza admitted to the hospital or ICU receive NA inhibitors.
Notably, the structure of mammalian NAs resembles bacterial
and viral NAs in that they all harbor a conserved F(Y)RIP domain
followed by a series of ‘‘Asp boxes’’ in the amino-terminal portion
of the protein.30 Therefore, we and others have speculated that
oseltamivir could also have an inhibitory effect on mammalian
NAs.12,31,32 Although previous literature suggests that the drug
has limited inhibitory activity against mammalian sialidases,
intriguing results were observed in in vitro and in vivo cancer
studies.33–35 Also, the clinical data showing that oseltamivir
has effects on platelets in individuals with ITP further support
this concept.11,12,32 The effect of oseltamivir on platelets has
also been demonstrated in individuals with dengue, where
desialylation of platelets occurs, and this effect was reduced
by oseltamivir.31 However, we were able to demonstrate that
immunocompetent mice treated with oseltamivir weremore sus-
ceptible to A. fumigatus infection because of the impaired killing
capacity of myeloid cells against the fungi. In vivo, NA activity
might come from the host cells4,36 or from the fungus.25 How-
ever, we also investigated a condition where we did not have
the actual Aspergillus infection but just exposed mice to oselta-
mivir and investigated the killing capacity of splenocytes
compared with mice not exposed to oseltamivir. We could
already demonstrate impairment of the killing capacity ex vivo
of splenocytes exposed to oseltamivir. Therefore, although we
do agree that fungus-derived NA could play a role during infec-
tion, at least the host NA is largely responsible for our observed
killing capacity of monocytes because of oseltamivir. This is in
line with previous studies that have elaborated the immunomod-
ulatory effect of oseltamivir in the setting of influenza infec-
tion.37,38 We also explored whether NA inhibition affects the sus-
ceptibility of mice under immunosuppression conditions. We
observed different outcomes in CS- and cyclophosphamide-
treated mice. NA inhibition increased the susceptibility to




invasive aspergillosis in CS-treated mice but not in mice treated
with cyclophosphamide. This suggested that the effects of
oseltamivir were dependent on myeloid cells. We observed
that oseltamivir impaired the A. fumigatus killing capacity of mu-
rine splenocytes and human PBMCs. Additionally, the fact that
NA inhibition by oseltamivir carboxylate did not have any effect
on cytokine and ROS induction in PBMCs supports our observa-
tion that the drug modulates anti-Aspergillus defense by impair-
ing the killing capacity of the cells.
SIGLEC receptors are a family of receptors that play a signifi-
cant role in regulating host immune responses.9 These receptors
bind sialylated structures on the surface of immune cells as well
as on pathogens.39 In the absence of a sialylated ligand,
SIGLECs are present in a cis transformation state, where they
are ‘‘masked’’ by dense sialic acid structures from adjacent re-
ceptors. Following cellular activation by exposure to a NA or
an encounter with higher-affinity ligands, these receptors are un-





Figure 4. Oseltamivir treatment impaired the fungal killing capacity of mouse splenocytes and human PBMCs
(A) Killing capacity of splenocytes from immunocompetent C57BL/6J mice treated with (red bars) or without (black bars) oseltamivir and infected with
A. fumigatus (1 3 106/mL) (empty bars) or left uninfected (striped bars).
(B and C) PBMCs and neutrophils were stimulated with A. fumigatus conidia (MOI of 4:1) in the presence or absence of oseltamivir carboxylate (n = 16). A killing
assaywas performed after 4 h of incubation at 37C. Cells were lysedwith H2O and plated on Sabouraud dextrose agar (SDA) in serial dilutions, and the remaining
CFUs were counted after 24-h incubation at 37C.
(D and E) ROS production from immune cells in lung homogenates of immunocompetentmice treatedwith or without oseltamivir and infected withA. fumigatus or
left uninfected.
(F and G) ROS induction from PBMCs and neutrophils stimulated with A. fumigatus conidia in the presence or absence of oseltamivir carboxylate (n = 11).
Data are shown as mean ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05.
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ligands. Binding of SIGLEC receptors to a sialic acid then signals
through downstream proteins, leading to activation or inhibition
of different immune functions.17 Based on this concept, it is inter-
esting to speculate that addition of NA can ‘‘open’’ the surface of
SIGLEC receptors, allowing them to bind to and recognize sialy-
lated A. fumigatus conidia and activation of downstream
signaling pathways. Currently, there are two known SIGLEC
families: the highly conserved group 1, which consists of siaload-
hesin, CD22, SIGLEC44, and SIGLEC15, and group 2, which
consists of CD33-related SIGLECs and varies among species.9
We identified SIGLEC15 as the only SIGLEC receptor that was
strongly induced in PBMCs stimulated with A. fumigatus conidia.
SIGLEC15 is expressed by myeloid cells40–42 and has been
described recently to play a role in cancer immunology, where
it suppresses T cell responses.40 SIGLEC15 binds preferentially
to the Neu5Aca2-6GalNAc- (sialyl Tn) structure.41 Moreover,
polymorphisms in the SIGLEC15 gene have been identified
recently as a risk factor for recurrent vulvovaginal candidiasis
(RVVC), and loss of this receptor is associated with altered cyto-
kine responses against the fungal pathogen Candida albicans.43
Our findings showed that PBMCs from individuals carrying the
same SNP as the one identified in the RVVC cohort
(rs2919643) had altered IL-1b and IFN-g production in response
to A. fumigatus conidia. Most importantly, our results demon-
strate that impairment of SIGLEC15 expression altered the killing
capacity of mononuclear myeloid cells against A. fumigatus. re-
cSIGLEC15 bound Aspergillus conidia, and knockdown of SI-
GLEC15 resulted in decreased killing capacity of PBMCs. This
effect was lost when Aspergillus conidia were treated with NA,
further supporting the concept that SIGLEC15, via recognition
of sialic acids on the surface of Aspergillus, regulates fungal
killing and that blocking NA alters this killing capacity. Our result
was different from those of a previous study by Jaeger et al.43
regarding the fact that SIGLEC15 is important for killing of
A. fumigatus but not C. albicans. Upon binding to its sialylated
ligand, SIGLEC15 recruits the adaptor protein DNAX adaptor
protein 12 (DAP12).18 DAP12 harbors an immunoreceptor tyro-
sine-based activating motif (ITAM) that, upon activation and
phosphorylation, eventually recruits Syk. DAP12-Syk signaling
subsequently induces other downstream targets, leading to
different effector mechanisms, such as cytokine production
and phagocytosis.44 Additionally, activation of DAP12-associ-
ated receptors, such as triggering receptors expressed on
myeloid cells (TREMs), could further amplify DAP12-mediated
signaling. TREM1, for instance, has been reported to mediate
immune responses against A. fumigatus conidia in experimental
fungal asthma.45 TREM2-DAP12 signaling is also crucial for
binding and uptake of bacteria46 but not C. albicans.47 It is inter-
esting to speculate that amplification of DAP12 signaling
induced by SIGLEC15 and other DAP12-associated receptors
is crucial for phagocytosis and killing of A. fumigatus but not
C. albicans.
NA activity is important for protective responses against
Aspergillus, and NA inhibitors might lead to decreased fungal
killing capacity and increase susceptibility to invasive pulmonary
aspergillosis. Furthermore, we identified SIGLEC15 as a
receptor with a role in anti-Aspergillus host defense, which un-
derscores the importance of sialic acids in host-pathogen inter-
action. These findings contribute to improving our understanding
of the pathogenesis of IAPA, particularly regarding use of NA in-
hibition in critically ill individuals with severe influenza. In these
people, inhibition of NA may be a crucial risk factor for develop-
ment of IAPA.
Limitations of study
In this study, we show that NA plays a role in host defense
against A. fumigatus. However, we did not report data regarding
the efficiency of host NAs in cleaving sialic acids from immune
cells and the relative inhibitory effect of these enzymes by osel-
tamivir. Additional experiments using recombinant mammalian
sialidases would provide more detailed information. Further-
more, more work is needed to determine the effect of oseltamivir
on other components of the antifungal response, including the
effect on different cell types and effector functions.
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Figure 5. The role of SIGLEC15 in the host response against A. fumigatus
(A and B) PBMCs or neutrophils were stimulated with A. fumigatus for 4 h in the presence or absence of exogenous C. perfringens NA (n = 14). Cells were then
lysed in H2O, and the remaining conidia were plated in serial dilutions on SDA and incubated for 24 h at 37
C.
(C) Gene expression profiling of SIGLEC genes, using Illumina Human HT-12 Expression BeadChip, in PBMCs stimulated with heat-killed A. fumigatus conidia for
4 and 24 h (n = 8).16
(D) Recombinant SIGLEC15 (recSIGLEC15) binding to A. fumigatus. Green, heat-killed A. fumigatus; blue, heat-killed A. fumigatus + secondary antibody (anti
immunoglobulin G [IgG]-Alexa 647); red, heat-killed A. fumigatus + recSIGLEC15 + secondary antibody.
(E) PBMCs were transfected with SIGLEC15 siRNA or scrambled control siRNA for 24 h prior to stimulation withA. fumigatus conidia. After 4 h of stimulation, cells
were lysed with H2O, and a killing assay was performed as described previously (n = 12). Data are represented as mean ± SEM (*p < 0.05).
(F) Killing capacity of PBMCs transfected with SIGLEC15 siRNA or control siRNA, as described previously, and stimulated with NA-treated or mock-treated
A. fumigatus conidia (n = 6).
(G)A. fumigatus-induced cytokine production fromPBMCs of individuals harboring a polymorphism in theSIGLEC15 gene (rs2919643) (TT = 12, CT/CC= 7). Data
are represented as mean ± SEM (**p < 0.01, *p < 0.05).
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
BV510 CD45 BioLegend RRID:AB_2561392
PerCp-Cy5.5 Ly-6C BioLegend RRID:AB_1727558
BV785 Ly-6G BioLegend RRID:AB_2566317
BV605 CD11c BioLegend RRID:AB_2562415
PE-Cy7 CD11b BioLegend RRID:AB_2033994
FITC I-A/I-E BioLegend RRID:AB_313321
Alexa Fluor 647 CD103 BioLegend 121410
APC F4/80 BioLegend RRID:AB_893481
PE Siglec F BD-Pharmigen 552126
CellROXTM Green Reagent Thermo Fisher Scientific C10444
Goat anti-Human IgG (H+L) Secondary Antibody,
Alexa Fluor 647
Thermo Fisher Scientific RRID:AB_2535862
Fungal strains
Aspergillus fumigatus V05-27 Isolated from patient N/A
Aspergillus fumigatus VP145_12 Isolated from patient N/A
Chemicals, peptides, and recombinant Proteins
Recombinant human SIGLEC15-Fc Bio-Techne 9227-SL-050
Phosphate Buffered Saline (PBS) Thermo Fisher Scientific 10010056
Tween-20 Sigma-Aldrich P1379
Sabouraud Glucose Agar with Chloramphenicol Sigma-Aldrich 89579
Neuraminidase from Clostridium perfringens Sigma N2876-6UN
RPMI 1640 Life Technologies 22409031
Gentamycin Centraform N/A
Pyruvate Invitrogen 11360
Ficoll-Paque Plus GE Healthcare 17-1440-03
Bovine Serum Albumin (BSA) Sigma A7030
iScript cDNA synthesis kit Bio-Rad 1708891





Oseltamivir carboxylate Bioconnect Life Sciences N/A
Lipofectamine RNAiMAX Transfection reagent Fisher Scientific 10514953
Ketamidor Mitcher Pharm N/A
Medetomidine (Dormtor) Ecuphar N/A
Cortisone-21 acetate Acros Organics 448960250
Baytril Bayer N/A
Cyclophosphamide
Oseltamivir (Tamiflu) Roche N/A
DMEM medium Thermo Fisher Scientific 10938025
Penicillin/Streptomycin Thermo Fisher Scientific 15140122
HEPES Buffer Solution Thermo Fisher Scientific 15630056
Fetal Bovine Serum Thermo Fisher Scientific 10500056
Collagenase D Sigma-Aldrich 11088858001
Bovine Serum Albumin (BSA) Sigma-Aldrich A7906
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Frank van
de Veerdonk at the Radboud University Medical Center, Nijmegen, the Netherlands (Frank.vandeVeerdonk@radboudumc.nl).
Materials availability
This study did not generate new reagents.
Data and code availability
RNA seq data on SIGLEC15 an NEU genes were extracted from an existing RNaseq dataset.16 The datasets were retrieved from
Gene Expression Omnibus (GEO) using identifier GEO Series accession number GSE162746.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
Peripheral Blood Mononuclear Cells (PBMCs) and neutrophils were isolated from venous blood of healthy volunteers after given
informed consent. All donors were over 18 years of age. To further validate the findings related to SIGLEC15, ex vivo cytokine
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Formalin Sigma-Aldrich HT501128
Percoll GE Healthcare 17089102
L-glutamine Sigma-Aldrich 25030081
Critical commercial assays
Human TNF-a ELISA Bio-Techne/R&D DY201
Human IL-1b ELISA Bio-Techne/R&D DY201
Human IL-8 ELISA IBL International M9318
Mouse TNF-a ELISA BioLegend 430904
Mouse IL-1b ELISA BioLegend 432604
Mouse IL-6 ELISA BioLegend 431304
Experimental Models: Organisms/strains
C57BL/6 mice, 8 weeks old, adult male Jackson Laboratory N/A
BALB/c mice, 10-weeks old, adult male Janvier, Le Genest, France N/A
Oligonucleotides
ON-Target plus human SIGLEC15 siRNA
smartpool (Dharmacon)
GE Healthcare L-023427-02-0005
ON-Target plus non-targeting pool siRNA GE Healthcare D-001810-10-05
Forward primer hSIGLEC15: 50-CGCG
GATCGTCAACATCTC-30
Biolegio (Primers designed by BLAST) N/A
Reverse primer hSIGLEC15: 50-GTTCG
GCGGTCACTAGGTG-30
Biolegio (Primers designed by BLAST) N/A
Forward primer hRPL37: 50-ATTGAA
ATCAGCCAGCACG-30
Biolegio (Primers designed by BLAST) N/A
Reverse primer hRPL37: 50- AGGAAC
CACAGTGCCAGAT-30
Biolegio (Primers designed by BLAST) N/A
Deposited data
RNA seq NCBI database GSE162746
Software and algorithms
GraphPad Prism 5.0 Graphpad Software https://www.graphpad.com
Kaluza Beckman Coulter N/A
FlowJo Tree Star Inc N/A
ImageJ software v1.50i NHI N/A




production was evaluated in PBMCs from healthy individuals that were recruited in the 200FG cohort study (http://www.
humanfunctionalgenomics.org).48 Ethical approval for all the donors in this study was obtained from the ethical board of Arnhem-Nij-
megen Medical Ethical Committee.
Animal subjects
For in vivo experiments, eight-week-old gender- and age- matched C57BL/6 mice were bred under specific-pathogen free condition
and kept at the Life and Health Sciences Research Institute (ICVS) Animal Facility. Animal experimentation was performed following
biosafety level 2 (BSL-2) protocols approved by the Institutional Animal Care and Use Committee (IACUC) of University of Minho and
the ethical and regulatory approvals were consented by the Ethical Subcommission for Life and Health Sciences (no. 074/016). To
determine the effect of oseltamivir on the susceptibility of cyclophosphamide-induced immunosuppressed mice, we also performed
experiments in 10-weeks old, adult male BALB/C mice (Janvier, Le Genest, France), after ethical approval from the animal ethics
committee of KU Leuven. All in vivo procedures were carried out according to national and European regulations.
METHOD DETAILS
Preparation of A. fumigatus conidia
Aspergillus fumigatus V05-27 was used for in vitro experiments with PBMCs and neutrophils. To prepare conidia, A. fumigatus was
grown on Sabouraud dextrose agar (SDA) for 7 days at 37C. Colonies were scraped from the agar surface and resuspended with
sterile Tween in PBS solution. To remove debris and hyphae fraction, the suspension was filtered over layers of sterile gauze and
washed twice with PBS. Conidia were counted and a final concentration of 1x107/mL was used in the experiments, unless otherwise
indicated. To acquire NA-treated A. fumigatus, conidia were either treated with 0.5 U/mL NA derived from Clostridium perfringens
(Sigma-Aldrich, St. Louis, Missouri, USA) or with a 25 mM KCl solution (mock) for 30 minutes at 37C in the presence of 2 mg/mL
polymyxin B, and washed twice with PBS.19,49 For in vivo experiments, Aspergillus fumigatus VP145_12 was used, with identical pro-
cedures for recovery of conidia.
Isolation and stimulation of PBMCs and neutrophils
PBMC fractions were isolated by Ficoll density gradient centrifugation (Ficoll-Paque Plus, GE Healthcare, Zeist, the Netherlands).
Cells were washed twice with Phosphate Buffered Saline (PBS) and suspended in RPMI 1640 medium (GIBCO, Invitrogen, Breda,
the Netherlands) supplemented with 5 mg/mL gentamicin, 1 mM pyruvate and 2 mM of L-glutamine (GIBCO). Cells were counted
in a coulter counter (Beckman Coulter, Pasadena, CA, USA) and adjusted to a final concentration of 2.5x106 cells/mL. After removal
of PBMC fractions, neutrophils were isolated from the remaining red blood cells by hypotonic lysis method.50 The remaining red
blood cells were lysed twice by adding hypotonic lysis buffer containing 155mMNH4Cl and 10mMKHCO3, which was further diluted
10 times. Afterward, cells were washed twice with cold PBS and resuspended in RPMI 1640 medium as mentioned previously.
To determine the role of NA on the host responses againstA. fumigatus, isolated PBMCs or neutrophils were plated onto a 96-wells
plate and stimulated with RPMI, NA-treated or mock-treated A. fumigatus conidia. In a separate set of experiments, cells were stim-
ulatedwithA. fumigatus conidia in the presence or absence of 0.2 U/mLC. perfringensNA. For in vitro experiments with NA inhibitors,
PBMCs or neutrophils were stimulated with A. fumigatus conidia or medium, and either treated with 0.1 mM oseltamivir carboxylate
(Bioconnect Life Sciences, the Netherlands) or remain untreated. The active compound of oseltamivir, which is oseltamivir carbox-
ylate, was used throughout the in vitro experiments. Culture supernatants were collected after 24 hours of incubation at 37C and 5%
CO2, and stored at 20C for further measurements of cytokines.
Mouse infection
At day 2 before infection and until day 2 after infection of the experimental protocol, 10 mg/kg oseltamivir was administered to the
C57BL/6J mice twice daily by oral gavage. The dose was chosen in order to achieve similar oral dose of 75 mg twice daily in hu-
mans.51 Control groups consisted of mice to which an equal volume of vehicle (sterile PBS) was administered. At day 0, mice
were challenged with 1 3 108 live conidia using a noninvasive intranasal (i.n.) infection procedure upon anesthesia with 75 mg/kg
of Ketamine (Ketamidor, Ritcher Pharma) and 1 mg/Kg of Medetomidine (Domtor, Ecuphar). At days 1 and 3 post-infection,
mice were sacrificed, and the lungs were PBS-perfused and excised, excluding the trachea and major bronchi. For assessment
of fungal burden, lung single-cell suspensions were serially diluted and plated on SDA. For histological analysis, the lungs were
perfused with PBS, excised and fixed with 10% buffered formalin solution at least 24 hours, processed and paraffin-embedded.
Lung paraffin-sections were stained with Hematoxylin and Eosin (H&E) for pathological examination. Images were acquired using
a BX61microscope (Olympus) and a DP70 high-resolution camera (Olympus). Morphometry analysis was carried out on slide images
using ImageJ software (v1.50i, NIH, USA).
For survival experiments, animals were immunosuppressed using 112 mg/kg cortisone 21-acetate (Acros Organics), which was
administered on days 3 and 1 before infection by subcutaneous (s.c.) injection. At day 0, mice were challenged with 13 107 live con-
idia as mentioned above. To avoid bacterial infections animals were treated with 50mg/mL of chloramphenicol in drinking water ad
libitum. Animals were daily weighted and sacrificed in case of 20% loss weight, severe ataxia or hypothermia and other severe
complications.




BALB/c mice were rendered immunosuppressed by intraperitoneal injection of cyclophosphamide (150 mg/kg) on days 4 and 1
prior to instillation of A. fumigatus conidia. A broad-spectrum antibiotic (Baytril, 5-8 mg/kg/day) was added to the drinking water
to prevent bacterial infection. Oseltamivir (10 mg/kg) was administered twice daily via oral gavage, from day 2 prior to infection until
day 2 after infection. Control mice were sham-treated in the same time period. Immunosuppressed mice were infected with 53 105
A. fumigatus conidia in 20 mL of PBS (C2/7/1 bioluminescent strain) via intranasal instillation. Directly after infection, the animals were
positioned upright until normal breathing resumed. Bioluminescence live-imaging assay and computed tomography (CT) scan took
place on day 4 prior to infection (baseline scan) and from day 1 after infection onward on a daily basis. During image acquisition,
animals were anesthetised with 1,5%–2% isoflurane (Abbott Laboratories, Queenborough, UK) in 100% oxygen (O2) administered
via a nasal cone. Body weight was monitored daily. The animals were killed when humane end points were reached, including a
strong loss in body weight (> 25%), lethargy and labored breathing. After euthanasia, the lungs were isolated for fungal load quan-
tification and histologic analysis.
Isolation of mouse splenocytes
Immunocompetent C57BL/6J mice infected with A. fumigatus conidia as above were sacrificed at day 1 and 3 post-infection with
posterior spleen excision. The excised spleen was milled into small fragments with a plunger end of a syringe and forced through
a 70-mm cell strainer (Corning Inc.) Upon washing the cells with cold and sterile PBS, the resulting cell pellet was resuspended in
2mL of pre-warmed (at 37C) ACK lysis buffer (0.15MNH4Cl, 10MmKHCO3 and 0.1mMEDTA). Subsequently, the cells were centri-
fuged at 1,600 rpm for 5 min at room temperature. Finally, the cells were counted and adjusted to a final concentration of 5x106 cells/
mL of pre-warmed RPMI (GIBCO, Thermo Fisher Scientific) enriched with 10% FBS (GIBCO, Thermo Fisher Scientific) and 200 mL of
the cellular suspension were seeded in round bottom 96-well plates (Corning Inc.).
Measurement of cytokines
Concentrations of TNF-a, IL-1b, and IL-8 were measured from the in vitro culture supernatants using enzyme-linked immunosorbent
assay (ELISA, R&D Systems), according to protocols supplied by the manufacturer. Cytokine measurements were performed on the
supernatants of lung single-cell suspensions on day 1 and 3 post-infection using ELISA MAX Deluxe Set kits (BioLegend) for mouse
IL-1b, IL-6, TNF-a, and IL-10 according to the manufacturer’s instructions.
Fungicidal/killing assay of Aspergillus fumigatus
Following isolation, PBMCs (5x105 cells) or neutrophils (2x105 cells) were plated onto a 96-well plate, and were stimulated with
A. fumigatus conidia (MOI 4:1), in a final volume of 200 mL. After incubation for 4 hours at 37C, cells were resuspended in H2O,
and lysates were plated on Sabouraud dextrose agar in serial dilutions. Colony-forming units (CFUs) were then counted after 24 hours
incubation at 37C.
To evaluate fungicidal activity of mice splenocytes, cells (13 106/well in 96-well plates) were infected with A. fumigatus conidia at a
1:5 ratio for 2 hours at 37C and 5%CO2. After incubation, culture plates were frozen at80C and thawed at 37C to cause cell lysis
and release of ingested conidia. Serial dilutions of cell lysates were plated on solid growth media and, following a 24 hours incubation
at 37C, the number of CFUs was enumerated and the percentage of CFU inhibition was calculated.
Measurement of ROS production in PBMCs and neutrophils
The production of reactive oxygen species (ROS) from PBMCs and neutrophils were measured by oxidation of luminol (3-amino-2,3,
dihydro-1,4-phtalazinedione). PBMCs (5x105) or neutrophils (5x105) were stimulated with A. fumigatus conidia (1x107/mL) or
zymosan (75 mg/mL) in a dark 96-well plate, together with 20 mL of 1 mM luminol. Chemiluminescence was measured using the Bio-
Tek Synergy HT reader at 37C for 1 hour. The production of ROS within the area under the curve (AUC) was analyzed.
Flow cytometry analysis
The interaction of SIGLEC15 and A. fumigatus was tested with flowcytometry. Recombinant human SIGLEC15-Fc (1mg/mL) (R&D
Systems) was incubated with A. fumigatus for 2 hours at 37C. Subsequently, samples were washed twice with PBS and 1%
BSA and stained with secondary antibody (Alexa 647 goat anti-human IgG (H+L) (Thermo Fisher) for 20 minutes. After additional
washing steps, samples were measured using CytoFLEX flow cytometer (Beckman Coulter). To determine the sialic acid properties
of A. fumigatus, conidia were incubated with either Maackia amurensis lectin (MAL) II, Sambucus nigra agglutinin (SNA), or Peanut
agglutinin (PNA), which bind to (a2, 3)-linked, (a2, 6)-linked sialic acids, or galactose residues, respectively. This was followed by la-
beling with a secondary fluorophore (Streptavidin) and analysis by flow cytometry. Data were analyzed using the Kaluza analyses
software version 1.5a.
After infection of the immunocompetent mice, the lungs and spleens were excised and collected in incomplete Dulbecco’s Modi-
fied Eagle Medium (iDMEM) culture medium (GIBCO, Thermo Fisher Scientific). The spleens were minced and forced through a 70-
mmcell strainer (Corning Inc., New York, USA) and red blood cells were lysedwith ACK lysis buffer (0.15MNH4Cl, 10MmKHCO3 and
0.1 mM EDTA). Perfused lungs were sliced in small fragments and digested at 37C for 30 min in incomplete DMEM culture medium
containing 1 mg/mL of Collagenase D (Sigma-Aldrich). Afterward, tissue was forced through a 70-mm cell strainer and remaining red
blood cells were lysed. Leukocytes were isolated by Percoll (GE Healthcare Bio-Sciences Ab, Uppsala, Sweden) density gradient




and, then resuspended in FACS buffer (PBS containing 2%FBS and 2mMEDTA). For surfacemarker staining, cell suspensions were
stained for 30 min on ice with the indicated antibodies. Pellets were washed and resuspended in fresh FACS buffer prior to analysis.
The composition of lung-infiltrating cells was determined using the combination of the following antibodies: BV510 CD45 (clone 30-
F11), PerCp-Cy5.5 Ly-6C (clone HK1.4), BV785 Ly-6G (clone 1A8), BV605 CD11c (clone N418), PE-Cy7 CD11b (clone M1/70), FITC-
I-A/I-E (clone M5/114.15.2), APC F4/80 (cloneBM8) and Alexa Fluor 647 CD103 (clone 2E7) from BD Biolegend. PE-Siglec-F (clone
E50-2440) was from BD-PharMingen. Data were obtained on a BD FACS LSRII instrument (BD Biosciences) and analyzed using
FlowJo (Tree Star Inc, Ashland, OR).
Measurement of ROS production in the lungs of the mice
Upon incubation with the different surface markers mentioned above, lung cells (1 3 105/well) were plated in 96-well plates (Sigma-
Aldrich), and 2.5mMCellROXGreen Reagent (Thermo Fisher Scientific) was added to eachwell and incubated at 4C for 30min in the
dark. Pellets were washed and resuspended in fresh FACS buffer prior to analysis. ROS production was measured on a BD FACS
LSRII instrument (BD Biosciences) according to the manufacturer’s instructions.
Silencing of SIGLEC15
PBMCs were isolated from healthy volunteers as described previously. Cells were transfected with either 25 nM SIGLEC15 siRNA or
scrambled control siRNA (SmartPool) using lipofectamine (Thermo Fisher Scientific) for 24 hours at 37C. Afterward, cells were stim-
ulated with live A. fumigatus conidia (1x107/mL) or medium for 4 hours and 24 hours. Subsequently, RNA was isolated using Trizol
(Thermo Fisher Scientific) and synthesized into cDNA. The efficiency of the silencing experiment was tested using qPCR with the
following primers: hSIGLEC15 (forward: 50-CGCGGATCGTCAACATCTC-30, reverse: 50-GTTCGGCGGTCACTAGGTG-30) and
hRPL37 (forward: 50-ATTGAAATCAGCCAGCACG-30, reverse: 50- AGGAACCACAGTGCCAGAT-30).
RNA-seq
RNA seq data on SIGLEC15 andNEU genes were extracted from an existing RNaseq dataset.16 PBMCs (1x106/well) were stimulated
with heat-killed A. fumigatus conidia (1x107/mL) or medium for 4 and 24 hours at 37C in 5% CO2. RNA was isolated using the mir-
VANA RNA isolation kit (Applied Biosystems) prior to RNA sequencing.16 The datasets were retrieved from Gene Expression
Omnibus (GEO) series with the accession number GSE162746.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical comparisons between groups were analyzed using Mann-Whitney-U-test or Wilcoxon signed rank test for paired
analysis. Data are presented as mean ± standard error of the mean (SEM). A p value of < 0.05 was considered statistically significant
(* = p < 0.05, ** = p < 0.01, *** = p < 0.001). Data were analyzed using GraphPad Prism software version 5.0 (La Jolla, CA, USA).
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